• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effects of risankizumab in patients with psoriasis previously treated with guselkumab: a case series.

作者信息

Lin Pin-Hsin, Tsai Tsen-Fang

机构信息

Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan.

Department of Dermatology, National Taiwan University Hospital, Taipei, Taiwan, Department of Dermatology, National Taiwan University College of Medicine, Taipei, Taiwan.

出版信息

Eur J Dermatol. 2021 Apr 1;31(2):251-252. doi: 10.1684/ejd.2021.4001.

DOI:10.1684/ejd.2021.4001
PMID:33875411
Abstract
摘要

相似文献

1
Effects of risankizumab in patients with psoriasis previously treated with guselkumab: a case series.
Eur J Dermatol. 2021 Apr 1;31(2):251-252. doi: 10.1684/ejd.2021.4001.
2
Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice.老年银屑病患者的抗白细胞介素-23 治疗：真实世界中 Guselkumab、Risankizumab 和 Tildrakizumab 的应用。
Clin Exp Dermatol. 2022 Mar;47(3):561-567. doi: 10.1111/ced.14979. Epub 2021 Nov 17.
3
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. Guselkumab，一种抗白细胞介素-23 单克隆抗体，与阿达木单抗治疗中重度斑块状银屑病的疗效和安全性比较：来自 III 期、双盲、安慰剂和阳性对照的 VOYAGE 2 试验的结果。
J Am Acad Dermatol. 2017 Mar;76(3):418-431. doi: 10.1016/j.jaad.2016.11.042. Epub 2017 Jan 2.
4
Risankizumab for severe psoriasis: a case of successful retreatment without induction after 15 months of discontinuation.司库奇尤单抗治疗重度银屑病：停药15个月后无需诱导治疗而成功再次治疗1例
Ital J Dermatol Venerol. 2024 Apr;159(2):199-200. doi: 10.23736/S2784-8671.23.07691-0.
5
Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison.古塞库单抗和司库奇尤单抗治疗银屑病：44周间接真实世界比较
J Am Acad Dermatol. 2021 Oct;85(4):1028-1030. doi: 10.1016/j.jaad.2021.01.025. Epub 2021 Mar 21.
6
Short-term effectiveness of biologics in patients with moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis.生物制剂治疗中重度斑块状银屑病患者的短期疗效：系统评价和网络荟萃分析。
J Dermatol Sci. 2020 Jul;99(1):53-61. doi: 10.1016/j.jdermsci.2020.06.003. Epub 2020 Jun 18.
7
Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.瑞莎珠单抗与优特克单抗治疗中度至重度斑块状银屑病的对比
Dermatol Ther. 2017 Sep;30(5). doi: 10.1111/dth.12507. Epub 2017 May 16.
8
Risankizumab in obese patients with moderate-to-severe plaque psoriasis: a 104-week, real-world, retrospective study.肥胖的中度至重度斑块状银屑病患者使用司库奇尤单抗的104周真实世界回顾性研究。
Arch Dermatol Res. 2024 Oct 9;316(9):667. doi: 10.1007/s00403-024-03419-w.
9
Resident Rounds. Part III A. Serendipitous improvement in moderate to severe acne in psoriasis patients treated with ustekinumab: a two-case series.住院医师查房。第三部分A。使用乌司奴单抗治疗的银屑病患者中重度痤疮意外改善：两例病例系列
J Drugs Dermatol. 2013 Jun 1;12(6):710-1.
10
Real-world effectiveness and safety of risankizumab in adult patients with plaque psoriasis: A 1-year international multicenter retrospective cohort study.司库奇尤单抗在成年斑块状银屑病患者中的真实世界有效性和安全性：一项为期1年的国际多中心回顾性队列研究。
J Am Acad Dermatol. 2024 Sep;91(3):513-515. doi: 10.1016/j.jaad.2024.03.048. Epub 2024 Apr 25.

引用本文的文献

1
Risankizumab for the Treatment of Moderate to Severe Psoriasis: Impact on Health-Related Quality of Life and Psychological Wellbeing.司库奇尤单抗治疗中度至重度银屑病：对健康相关生活质量和心理健康的影响。
Clin Cosmet Investig Dermatol. 2023 Jan 25;16:221-229. doi: 10.2147/CCID.S296544. eCollection 2023.